体重管理第一股亮相 先为达生物递表港交所

Core Viewpoint - Hangzhou Sciwind Biotech Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to commercialize its core product, XW003, a GLP-1 receptor agonist for weight management and type 2 diabetes treatment [1][2]. Company Overview - Sciwind Biotech is a near-commercial stage biopharmaceutical company focused on addressing urgent medical needs in the weight management sector [1]. - The company has developed a comprehensive pipeline of drug candidates targeting obesity and related common diseases, including overweight, obesity, type 2 diabetes, and metabolic-related conditions [1]. Product Pipeline - The product pipeline is anchored by XW003, which is expected to be the world's first cAMP-biased GLP-1 receptor agonist [1]. - The company employs a "pipeline-in-a-product" strategy to support sustainable innovation in weight management, providing customized solutions to meet diverse medical needs [2]. Strategic Partnerships - In 2024, Sciwind Biotech will collaborate with Hk Inno.N to grant rights for XW003 in South Korea [2]. - In January 2025, the company reached an agreement with Verdiva Bio to grant exclusive global development and commercialization rights for oral formulations of XW003 outside Greater China and South Korea, with a potential total deal value exceeding $2.4 billion, including nearly $70 million in upfront payments [2].